New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 7, 2014
07:42 EDTEPZMEpizyme initiates pediatric MLL-r proof-of-concept study for leukemia candidate
Epizyme initiated a Phase 1b open-label clinical study of EPZ-5676 in pediatric patients with acute leukemias bearing a rearrangement of the MLL gene. This Phase 1b study is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses of EPZ-5676 in patients between the ages of 3 months and 18 years and to provide a preliminary assessment of efficacy. Expected data disclosure date is in 2H14.
News For EPZM From The Last 14 Days
Check below for free stories on EPZM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
08:05 EDTEPZMEpizyme names Peter Ho as Chief Development Officer
Epizyme announced the appointments of Peter Ho, M.D., Ph.D., as Chief Development Officer and Michael Shih, J.D. as Vice President, Business Development. Ho will lead Epizyme’s clinical development, regulatory and translational medicine functions. Shih will lead Epizyme’s partnership strategy and execution.
September 12, 2014
10:00 EDTEPZMOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:27 EDTEPZMEpizyme initiated with a Buy at Mizuho
Target $35.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use